A Randomized, Single-Center, Open-Label, Crossover Study Comparing the Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Open-Angle Glaucoma or Ocular Hypertension. (Constellation)

NCT01707381 Phase 2 COMPLETED Results posted

This clinical investigation is being performed to compare the effect of BOL-303259-X dosed once daily (QD) with timolol maleate 0.5% dosed twice daily (BID) in reducing intraocular pressure (IOP) measured over a 24-hour period in subjects with open-angle glaucoma (OAG) or ocular hypertension (OHT).

Details

Lead sponsor	Bausch & Lomb Incorporated
Phase	Phase 2
Status	COMPLETED
Enrolment	25
Start date	2012-11
Completion	2014-02

Conditions

• Ocular Hypertension
• Open Angle Glaucoma

Interventions

• BOL-303259-X
• Timolol maleate

Primary outcomes

• 24 Hour IOP — after 4 weeks of treatment
  Supine intraocular pressure (IOP) measured in the study eye following 4 weeks of treatment

Countries

United States